PURPOSE: We retrospectively evaluated the feasibility and safety of a modified prophylactic donor lymphocytes infusion (DLI) approach in advanced leukemia. MATERIALS AND METHODS: Thirty-three patients with advanced leukemia received modified prophylactic DLI; that is, granulocyte colony-stimulating factor-primed peripheral blood progenitor cells instead of steady-donor lymphocyte harvests were used, and a short-term immunosuppressive agent (cyclosporine A or methotrexate 10 mg once per week for 2 to 4 weeks) was used for prevention of DLI-associated graft versus host disease (GVHD) after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. RESULTS: Thirty-nine infusions were performed in 33 patients. The mononuclear cells and median CD3+ cells infused for DLI were 1-2 x 10(8) and 0.93 x 10(6) per kilogram, respectively. Six patients experienced II-IV-grade acute GVHD. Twenty patients developed chronic GVHD. No GVHD-related death or transfusion-related pancytopenia was observed. With an 18-month median follow-up, 16 patients were in disease-free survival, and overall survival at 1 and 1.5 years was 69.0% and 50.2%, respectively. CONCLUSION: The modified prophylactic DLI strategy might represent a step forward in the treatment of advanced leukemia.
PURPOSE: We retrospectively evaluated the feasibility and safety of a modified prophylactic donor lymphocytes infusion (DLI) approach in advanced leukemia. MATERIALS AND METHODS: Thirty-three patients with advanced leukemia received modified prophylactic DLI; that is, granulocyte colony-stimulating factor-primed peripheral blood progenitor cells instead of steady-donor lymphocyte harvests were used, and a short-term immunosuppressive agent (cyclosporine A or methotrexate 10 mg once per week for 2 to 4 weeks) was used for prevention of DLI-associated graft versus host disease (GVHD) after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. RESULTS: Thirty-nine infusions were performed in 33 patients. The mononuclear cells and median CD3+ cells infused for DLI were 1-2 x 10(8) and 0.93 x 10(6) per kilogram, respectively. Six patients experienced II-IV-grade acute GVHD. Twenty patients developed chronic GVHD. No GVHD-related death or transfusion-related pancytopenia was observed. With an 18-month median follow-up, 16 patients were in disease-free survival, and overall survival at 1 and 1.5 years was 69.0% and 50.2%, respectively. CONCLUSION: The modified prophylactic DLI strategy might represent a step forward in the treatment of advanced leukemia.
Authors: E P Alessandrino; P Bernasconi; D Caldera; A Colombo; L Malcovati; G Martinelli; M Bonfichi; G Pagnucco; L Salvaneschi; C Bernasconi Journal: Bone Marrow Transplant Date: 1999-03 Impact factor: 5.483
Authors: R Pawson; M N Potter; P Theocharous; M Lawler; M Garg; J A Yin; K Rezvani; C Craddock; S Rassam; H G Prentice Journal: Br J Haematol Date: 2001-12 Impact factor: 6.998
Authors: John E Levine; Thomas Braun; Samuel L Penza; Patrick Beatty; Kenneth Cornetta; Rodrigo Martino; William R Drobyski; A John Barrett; David L Porter; Sergio Giralt; Jose Leis; Houston E Holmes; Matthew Johnson; Mary Horowitz; Robert H Collins Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: R A Clift; C D Buckner; F R Appelbaum; G Schoch; F B Petersen; W I Bensinger; J Sanders; K M Sullivan; R Storb; J Singer Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: J C Biggs; M M Horowitz; R P Gale; R C Ash; K Atkinson; W Helbig; N Jacobsen; G L Phillips; A A Rimm; O Ringdén Journal: Blood Date: 1992-08-15 Impact factor: 22.113
Authors: H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari Journal: Blood Date: 1995-09-01 Impact factor: 22.113
Authors: S Slavin; E Naparstek; A Nagler; A Ackerstein; S Samuel; J Kapelushnik; C Brautbar; R Or Journal: Blood Date: 1996-03-15 Impact factor: 22.113
Authors: Kambiz Bagheri; Kamran Alimoghadam; Ali Akbar Pourfathollah; Zuhair Muhammad Hassan; Jamshid Hajati; Seyyed Mohammad Moazzeni Journal: Pathol Oncol Res Date: 2008-09-20 Impact factor: 3.201
Authors: P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler Journal: Bone Marrow Transplant Date: 2016-06-13 Impact factor: 5.483